Asia’s medical device manufacturing strained amid Strait of Hormuz crisis
The disruption in naphtha supplies due to the ongoing Iran conflict, leading to the blockade of the Strait of Hormuz is significantly impacting medical device manufacturing in Asia by increasing raw material costs, forcing production cuts, and complicating logistics for crucial components. Naphtha is a key ingredient for many plastics used in medical devices, and its supply chain is heavily reliant on Middle Eastern crude oil shipments through the Strait of Hormuz, according to reports.
Impact on Naphtha supply, petrochem production
The escalating conflict in the Middle East has severely constrained naphtha supplies, a critical petrochemical feedstock. Asian petrochemical producers, which source a substantial portion of their naphtha from the Middle East, are experiencing significant disruptions. The Strait of Hormuz, a vital waterway through which about a fifth of global oil trade passes, has seen tanker traffic halted due to Iranian attacks on oil tankers, leading to supply chain strain, according to a report from ICIS.
Several Asian countries are directly affected
In Japan, already multiple petrochemical firms, including Maruzen Petrochemical and Mitsui Chemical, have reportedly canceled naphtha import tenders and announced production cuts due to concerns over strained supplies. According to a report, over 40% of Japan’s naphtha imports come from the Middle East, and at least six of its 12 ethylene production facilities are reducing output. Companies like Shin-Etsu Chemical and Tosoh Corp. are increasing prices for products like polyvinyl chloride resin and polyethylene, citing rising naphtha costs.
Over in South Korea, the largest importer of Middle East naphtha in Asia, sourcing 54% of its supply via the Strait of Hormuz, is also facing significant concerns from its petrochemical producers. Companies such as Lotte Chemical, GS Caltex, LG Chem, and SK Energy need to decide within weeks whether to find alternative sources or cut output. The South Korean government has implemented emergency measures to restrict naphtha exports by oil refiners due to shortages.
Over in Singapore, disruptions to oil flows are tightening naphtha supply, a key feedstock for plastics used in medical items like syringes and catheters , while makers are reportedly increasing prices, with some anticipating rises of up to 50%. Singaporean firms like PCS and Aster Chemicals and Energy have declared “force majeure” on shipments and cut crude runs. Likewise, Indonesia’s Chandra Asri declared force majeure on all contracts due to raw material supply disruptions caused by the Middle East conflict.
Related: From Epic Fury to Epic Risks: global healthcare in peril
Grim times for medical device manufacturing
The instability in naphtha supply directly affects the manufacturing of medical devices, as naphtha is a primary raw material for plastics, such as polyethylene and polypropylene, used in various medical products. This has led to rising production costs and potential product price increases. These increased costs for essential materials will likely be passed on to consumers.
The situation puts chain supply in a preacriuos situation. As conflict takes a worse turn, existing vulnerabilities in the medical device supply chain are also exacerbated. According to an article in Think Global Health
, reliance on specific transport hubs and fragile cold chains shows the need for diversification. While countries like Singapore maintain diversified sources and sufficient stockpiles, many in Africa face supply shocks due to limited inventories. The World Health Organization (WHO) has reported deficitsin vulnerable nations, with its Dubai hub paused amid airspace disruptions.
Asian countries weathering the storm
To cope with the uncertainty, manufacturers are shifting from “just-in-time” to “just-in-case” supply chain approaches, building buffer stocks, and securing secondary suppliers. However, these are often longer-term solutions that do not address immediate challenges. Some Chinese enterprises are relocating production capacity to Southeast Asia, the Middle East, or Europe, and increasing R&D investment to enhance resilience.
At the end of the day, the conflict’s impact extends beyond naphtha to other critical medical components and logistics. Based on the Think Global Health article, the war has disrupted major logistics corridors, including the Strait of Hormuz and Gulf air hubs, causing global supply delays and higher freight costs. Marine insurance premiums have surged, with war coverage nearly doubling for Red Sea routes and rising over 1,000% for vessels in the Strait of Hormuz.
The conflict also threatens the global helium supply, with Qatar as the world’s second-largest producer. Helium is critical for cooling MRI machines, and prolonged disruptions could raise prices and strain procurement for the roughly 50,000 machines in use worldwide.
As the Asian region fortifies its resilience to weather economic challenges, petrochemical producers are responding to naphtha supply constraints by reducing output, declaring force majeure, exploring alternative feedstocks, and seeking government support until the impact of the conflict eases.
Category: Top Story
